Post-hoc analyses showed that patients who benefited most from angiotensin II administration were those with the most severe shocks with a relative angiotensin II deficiency, (38) those with markedly elevated serum renin concentrations at baseline (39) and those with acute kidney injury requiring renal replacement therapy (40). This evidence concerns the gene AGT and acute kidney injury.